drugset
drugset / Trial / NCT07723118

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

NCT07723118 ↗

Phase 1 Completed 10 enrolled Mirati Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to assess the pharmacokinetics, safety and tolerability of single-dose Adagrasib (BMS-986503) in healthy participants of Japanese descent

Timeline

Start
2026-08-05
Primary completion
2026-09-08
Completion
2026-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Adagrasib Small molecule — —

Indications

No indication recorded.